TOP TEN perturbations for 1117_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1117_at
Selected probe(set): 205627_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1117_at (205627_at) across 6593 perturbations tested by GENEVESTIGATOR:

CML study 1 / B-CLL study 5

Relative Expression (log2-ratio):5.336506
Number of Samples:75 / 441
Experimental CML study 1
Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

precursor-B-ALL study 1 (t(1;19)(q23,q13)) / normal bone marrow sample

Relative Expression (log2-ratio):-5.068265
Number of Samples:36 / 74
Experimental precursor-B-ALL study 1 (t(1;19)(q23,q13))
Bone marrow samples of patients with precursor B-ALL (t(1;19)(q23,q13)/E2A-PBX1).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

B-ALL study 1 (hyperdiploid) / normal bone marrow sample

Relative Expression (log2-ratio):-5.0340176
Number of Samples:40 / 74
Experimental B-ALL study 1 (hyperdiploid)
Bone marrow samples of patients with hyperdiploid B-ALL (hyperdiploid karyotype).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

B-CLL study 5 / normal bone marrow sample

Relative Expression (log2-ratio):-4.8905907
Number of Samples:441 / 74
Experimental B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

precursor-B-ALL study 1 (t(11q23)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.864456
Number of Samples:70 / 74
Experimental precursor-B-ALL study 1 (t(11q23))
Bone marrow samples of patients with precursor B-ALL (t(11q23)/MLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

precursor-B-ALL study 1 (t(12;21)(p12,q22)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.846184
Number of Samples:58 / 74
Experimental precursor-B-ALL study 1 (t(12;21)(p12,q22))
Bone marrow samples of patients with precursor B-ALL (t(12;21)(p12,q22)/TEL-AML1).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

c-ALL/pre-B-ALL study 1 / normal bone marrow sample

Relative Expression (log2-ratio):-4.8449945
Number of Samples:232 / 74
Experimental c-ALL/pre-B-ALL study 1
Bone marrow samples of patients with c-ALL/pre-B-ALL (without t(9;22)(q34,q11)/BCR-ABL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

SKVCR2.0 / SK-OV-3

Relative Expression (log2-ratio):4.838949
Number of Samples:2 / 2
Experimental SKVCR2.0
Human metastatic cancer cell line derived from the ascites of a patent with adenocarcinoma of the ovary. Vincristine-resistant derivative of the ovarian adenocarcinoma cell line SKOV3 capable of growing in media with 2.0 µg/ml vincristine drug. Parental cell line:: SK-OV-3 Synonyms:SKVCR 2.0; SK VCR 2 Cellosaurus code:
Control SK-OV-3
Human metastatic cancer cell line derived from the ascites of a patient with ovarian serous cystadenocarcinoma. Synonyms:SKOV-3; SK.OV.3; SKOV3; SKO3 Cellosaurus code:

CD44s overexpr. study 1 / normal HEK-293 cell sample

Relative Expression (log2-ratio):4.6121826
Number of Samples:3 / 3
Experimental CD44s overexpr. study 1
Human embryonic kidney cell line HEK-293 transfected with pcDNA3.1(-) vector containing codon-optimized human CD44 sequence for expression.
Control normal HEK-293 cell sample
Untransfected, native human embryonic kidney cell line HEK-293 cell samples.

c-ALL/pre-B-ALL study 1 (t(9;22)(q34,q11)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.571577
Number of Samples:121 / 74
Experimental c-ALL/pre-B-ALL study 1 (t(9;22)(q34,q11))
Bone marrow samples of patients with c-ALL/pre-B-ALL (t(9;22)(q34,q11)/BCR-ABL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.